Rius Medical

Product / Service Summary

Products - cells therapy with native red blood cells and red blood cells for drug delivery alongside recombinant Plasma Protein therapeutics.


Life Science & Healthcare

Startup Stage

Technology Development/ Production

B2B

Description

Cell & Gene Therapy will shape the future of medicine, when novel technologies proceed beyond the primary goals of safety and efficacy. Uneconomical manufacturing represents a major roadblock to the sustainable commercialisation of cellular products.

Is it a ridiculous idea to improve care and reduce cost while implementing highly disruptive healthcare technology? Rius Medical has the solution.


USP

Creation of Value within 2 years through a platform technology for FIVE assets being proprietary cell lines for drug delivery, worth 130 million euro upfront payment/revenue at 3 years.

Multiple partnership opportunities at 3 years following initial investment through out-licensing that bring subsequent milestones payment/revenue.

Re-invent blood transfusion with ready-to-use, off-the-shelf enhanced red blood cells, doing more than simply carry Oxygen as cargo.


Rius Medical Team Members


Startbase Data

Added: 20.05.2017
Updated: 30.08.2019
Claimed: 13.08.2019
Verified: 19.09.2019
  • Validated team members on Startbase
  • Registered at a German Handelsregister
  • Headquarter located in Germany
  • Scalable Business Model
  • Innovative Business Model
  • Founders are still involved
  • Founders still hold shares
Rius Medical
An EXIT opportunity at 3 years for early investors resulting in EUR 54 million financial benefit for FIVE products, if not EUR 10,5 million financial benefit for TWO products.